Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Jazz Pharmaceuticals
Bayer
National Institutes of Health Clinical Center (CC)
AstraZeneca
Psyence Australia Pty Ltd
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
University of California, Irvine
Daiichi Sankyo
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
University of Chicago
Merck Sharp & Dohme LLC
Telix Pharmaceuticals (Innovations) Pty Limited
University of California, Irvine
National Institutes of Health Clinical Center (CC)
Beijing Biostar Pharmaceuticals Co., Ltd.
Albert Einstein College of Medicine
Rain Oncology Inc
Laval University
Universitair Ziekenhuis Brussel
Convalife (Shanghai) Co., Ltd.
pharmaand GmbH
Sheba Medical Center
Instituto do Cancer do Estado de São Paulo
OncXerna Theraputics, Inc.
ExcellaBio LLC
MultiVir, Inc.
Eli Lilly and Company
UMC Utrecht
Ipsen
Wake Forest University Health Sciences
Roswell Park Cancer Institute
Hospital General Universitario Gregorio Marañon
Uppsala University
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Northwestern University
NYU Langone Health
Wuhan University